CardioDx, which sells diagnostic tests for cardiovascular diseases, revived plans for its upcoming IPO in an amendment filed on Monday. The Palo Alto, CA-based company postponed its IPO in November 2013 citing poor market conditions. The company had previously filed to raise $75 million by offering 5.0 million shares at a range of $14 to $16.
CardioDX, which was founded in 2003 and booked $8 million in sales for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol CDX. It initially filed confidentially on July 24, 2013. Jefferies and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
